NCT01784978View on ClinicalTrials.gov

Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

February 12, 2013

Primary Completion Date

May 8, 2017

Study Completion Date

May 8, 2017

Conditions
Metastatic Renal Cell Carcinoma
Interventions
DRUG

Sunitinib

50 mg pd

DRUG

Everolimus

10 mg pd

Trial Locations (10)

11528

ALEXANDRA General Hospital of Athens, Athens

28026

Hospital Universitario 12 de Octubre, Madrid

28040

Hospital Clínico San Carlos, Madrid

28050

Clara Campal. Hospital Sanchinarro, Madrid

33006

Hospital Universitario Central de Asturias, Oviedo

39008

Hospital Marqués de Valdecilla, Santander

Unknown

Hopital Bordeaux University, Bordeaux

Hospital Universitario Virgen de la Victoria, Málaga

Hospital General Universitario de Valencia, Valencia

08003

Hospital del Mar, Barcelona

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

collaborator

Pivotal S.L.

INDUSTRY

lead

Associació per a la Recerca Oncologica, Spain

OTHER

NCT01784978 - Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer | Biotech Hunter | Biotech Hunter